7 Cheap Stock Picks With Huge Upside to Research

Finding a cheap stock with huge upside requires more than spotting a low share price or a large analyst price target. The useful question is whether a business can generate substantially more value per share than its purchase price implies, without requiring an implausible turnaround.

The seven companies below offer different research angles: payments profitability, healthcare margins, pharmaceutical product transitions, banking efficiency, automotive cash generation, Chinese technology businesses and telecom cash flow. Each has an identifiable route to a higher valuation, alongside risks that could prevent it.

This is a valuation-dependent research list, not a declaration that all seven stocks are cheap today. It does not use live quotes or current valuation multiples. Before investing, check the latest filings, share price, debt position and corporate developments. Some candidates may already have recovered enough to eliminate the opportunity.

Seven candidates and the valuation question behind each

A low-priced share can represent an expensive business, while a higher-priced share can represent an inexpensive one. Market capitalization, debt, sustainable earnings and the number of shares outstanding matter more than the price of one share.

When researching a cheap stock with huge upside, start with the business improvement needed to justify your valuation, then ask whether the available evidence supports it.

1. PayPal (PYPL): research cash generation, not payment volume alone

PayPal's investment case centers on the gap between processing more payments and earning more money from them. Branded checkout and unbranded processing have different economics, so aggregate payment volume cannot establish whether shareholder value is improving.

Start with the company’s investor materials. Examine transaction-margin dollars, operating expenses, stock-based compensation and free cash flow. Then check whether repurchases actually reduce diluted shares outstanding rather than merely offset employee equity awards.

PayPal could qualify as a cheap stock with huge upside if its purchase valuation assumes weak long-term economics but the business delivers durable cash-flow growth per share.

What could unlock value: Better checkout conversion, stronger monetization, cost discipline and repurchases made below a defensible estimate of intrinsic value. The thesis should work without assuming a return to a previous peak valuation.

What could break the thesis: Competitive pressure from wallets, card networks and merchant platforms could weaken pricing or customer engagement. Higher processing volume would offer little comfort if incremental transactions generate inadequate profit.

Research hurdle: Build a valuation with modest revenue growth and no multiple expansion. If that produces an unattractive return, the investment depends heavily on a market rerating rather than business performance.

2. CVS Health (CVS): test whether healthcare margins can normalize

CVS combines insurance through Aetna, pharmacy benefit management through Caremark and pharmacy-related operations. Those businesses create multiple earnings sources, but they also make consolidated results harder to interpret.

Review the latest CVS financial disclosures by segment. For insurance, focus on the medical benefit ratio, which measures medical costs relative to premium revenue. Unexpected utilization, inadequate pricing or unfavorable membership changes can undermine earnings even when revenue grows.

The central question is whether premiums, benefits and operating decisions can support acceptable margins without damaging the franchise. Do not assume historical profitability automatically represents the correct destination.

A cheap stock with huge upside must offer more than a rebound in adjusted earnings; CVS also needs cash generation that supports its financial obligations.

What could unlock value: Better underwriting, more disciplined execution and a credible path to stronger cash generation after necessary investment.

What could break the thesis: Persistent medical-cost pressure, reimbursement changes, pharmacy economics or integration difficulties could make a seemingly temporary earnings shortfall more durable.

Research hurdle: Model the major segments separately. Treat management adjustments cautiously, particularly when supposedly exceptional expenses recur. Distinguish accounting earnings from cash that can actually support debt reduction or shareholder distributions.

3. Bristol Myers Squibb (BMY): value the patent transition explicitly

Pharmaceutical stocks can look inexpensive when current earnings are supported by medicines facing future competition. A low earnings multiple may therefore reflect a declining earnings base rather than an overlooked bargain.

For Bristol Myers Squibb, research the transition from older franchises, including Revlimid, toward newer products and pipeline assets. Use the company’s financial and pipeline disclosures to build a product-level revenue bridge rather than applying one growth rate to the entire company.

Separate products already generating commercial revenue from investigational medicines. Clinical progress does not guarantee approval, reimbursement or commercial success.

Bristol Myers Squibb becomes a potential cheap stock with huge upside only when a conservative estimate of replacement cash flow supports a value above the purchase price.

What could unlock value: Successful launches, broader approved indications and evidence that newer medicines can replace enough declining cash flow to sustain shareholder value.

What could break the thesis: Trial failures, competing treatments, pricing pressure or acquisitions that consume capital without producing adequate returns.

Research hurdle: Assign probabilities to uncertain pipeline outcomes and include ongoing research spending. Test dividend coverage after debt obligations and investment needs. A high yield does not compensate for an investment case that requires every major development program to succeed.

4. Citigroup (C): investigate the reason for any book-value discount

Banks require a different valuation framework from industrial or software companies. For Citigroup, tangible book value per share and return on tangible common equity are useful starting points, alongside credit quality, capital requirements and funding costs.

A bank trading below tangible book value is not automatically mispriced. If sustainable returns remain below its cost of equity, a discount can be economically justified. Check the latest Citi financial reports for evidence that operating changes are improving returns, not simply reducing reported expenses temporarily.

Citigroup could be a cheap stock with huge upside if a valuation discount persists while sustainable returns improve enough to make that discount difficult to justify.

What could unlock value: A simpler operating structure, stronger expense discipline and improved capital productivity, subject to regulatory constraints.

What could break the thesis: Credit deterioration, persistent control-related costs or restructuring expenses that fail to produce lasting benefits.

Governance deserves attention in a turnaround. This French-language introduction to independent director, board advisor and operating-partner roles provides background on different leadership functions. Citi’s own proxy statement and filings remain the evidence for who is accountable and how incentives are structured.

Research hurdle: Estimate a sustainable return on tangible common equity before choosing a justified price-to-book multiple. Do not start with a desired share price and work backward.

5. General Motors (GM): normalize profits across the vehicle cycle

Automakers can appear cheapest near the top of an earnings cycle. Strong pricing and favorable vehicle mix may temporarily lift profits, making a low price-to-earnings ratio less attractive than it looks.

For GM, separate the automotive business from its financing operations. Financial-services borrowing should not be treated identically to industrial debt, but the financing business still brings credit, funding and residual-value risks.

Use GM’s financial disclosures to examine automotive cash generation after capital spending. Stress-test weaker pricing, softer demand, labor costs, trade restrictions and the capital required for product transitions.

The case for GM as a cheap stock with huge upside should survive ordinary cyclical pressure rather than depend on unusually favorable vehicle economics.

What could unlock value: Disciplined investment, durable vehicle profitability and repurchases that reduce the share count at attractive valuations.

What could break the thesis: A downturn could combine falling margins with financing losses or heavier investment requirements. Buybacks cannot rescue a business whose sustainable earnings deteriorate faster than its share count falls.

Research hurdle: Value midcycle earnings and cash flow, then run a recession scenario. Check liquidity, pension commitments and other obligations before treating reported cash as excess capital available to shareholders.

6. Alibaba (BABA): separate operating value from ownership risk

Alibaba offers exposure to commerce, cloud computing and other businesses, but a valuation based only on operating performance misses important risks for US investors.

Start with the group’s investor disclosures. Examine segment profitability, investment needs, share-based compensation and cash available for shareholder distributions. A sum-of-the-parts valuation can help, provided it does not assign optimistic values to every business or count the same cash twice.

Also understand the ADR structure, the relevant share-conversion terms and the variable interest entity arrangements described in filings. Contractual exposure through a VIE is not equivalent to direct equity ownership of the underlying Chinese operating entities.

Alibaba may be a cheap stock with huge upside if conservative operating assumptions support substantial value after applying an explicit discount for these additional risks.

What could unlock value: Better monetization, profitable cloud growth, disciplined investment and distributions or repurchases that benefit remaining shareholders.

What could break the thesis: Competition, domestic economic weakness, regulation, geopolitical restrictions or limitations on investors’ ability to realize underlying business value.

Research hurdle: Test an outcome in which the valuation discount persists. A thesis that works only if investors eventually assign a US technology-company multiple is relying on an uncertain change in market perception.

7. Verizon (VZ): distinguish dividend income from price upside

Verizon represents a different proposition from a speculative turnaround. Its research case rests on recurring service revenue, network economics and cash available after substantial capital requirements.

Review Verizon’s investor reports for service revenue, customer retention, capital spending, debt maturities and free cash flow. Evaluate the dividend against cash remaining after necessary investment, not against adjusted earnings alone.

A high dividend yield does not establish that Verizon is a cheap stock with huge upside. A large share-price gain would require a stronger case, such as sustained cash-flow growth combined with a valuation that understates that durability.

What could unlock value: Improving customer economics, disciplined promotions and debt reduction that increases financial flexibility. A less demanding financing environment could help, but should not be the foundation of the thesis.

What could break the thesis: Price competition, expensive customer acquisition, refinancing pressure or network spending that produces insufficient incremental returns.

Research hurdle: Separate expected dividend income from potential capital appreciation. If your analysis supports mainly an income return, classify the stock accordingly. There is no reason to force every apparently inexpensive business into a high-upside category.

How to value a cheap stock with huge upside

Use explicit assumptions rather than an analyst target as the foundation of your decision. Here is a purely hypothetical example, unrelated to any company above:

At a hypothetical $20 purchase price, the base case implies 50% price upside and the bear case implies a 28% loss. Neither figure is a probability-weighted expected return, and both exclude dividends, taxes and trading costs. The time required to reach an outcome also matters.

The model is useful only if you can explain the cash-flow assumptions, share count and multiples. For a cheap stock with huge upside, the discount should survive reasonable changes to those inputs rather than disappear after one small revision.

Before committing money, test the upside case against evidence that could disprove it. Write down the operating result that would invalidate your thesis and the filing or earnings release where you expect to observe it.

Frequently asked questions

Which of these seven stocks has the most upside? There is no defensible ranking without current prices and updated financial information. The largest modeled gain may also depend on the least reliable assumptions. Compare downside, financing needs and the time required for improvement alongside potential returns.

Are stocks under $10 safer or better bargains? No. Share price reflects how ownership is divided, not whether the business is inexpensive. Low-priced stocks can also face dilution, limited liquidity or financial distress. None of the candidates here is selected because of a particular share-price threshold.

What is the best way to invest $5,000 in these ideas? A seven-stock list is not a portfolio allocation. Consider emergency savings, time horizon, diversification and existing exposures before selecting individual companies. A cheap stock with huge upside can still be unsuitable if its losses would compromise money you need soon.

Should I buy all seven to diversify? Not automatically. Different sectors can share economic risks, and owning seven individual stocks still leaves substantial company-specific exposure. Evaluate whether an upside candidate fits your existing portfolio before adding it.

Compare the opportunity with your existing holdings

Once a candidate passes your valuation work, examine what it adds to your portfolio. A new ticker may duplicate risks you already hold through individual stocks or funds.

Upside Invest lets you compare portfolios using verified investor holdings, explore sector and theme trends and review return and Sharpe metrics through private, anonymous profiles. Use that information to challenge your allocation, not as proof that another investor’s position will outperform.

The practical next step is to choose one candidate, read its latest disclosures and build a conservative valuation before considering a purchase.